0.05Open0.05Pre Close0 Volume20 Open Interest1.00Strike Price0.00Turnover474.90%IV61.85%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0502Delta0.0586Gamma49.80Leverage Ratio-0.0110Theta0.0000Rho-2.50Eff Leverage0.0004Vega
Esperion Therapeutics Stock Discussion
Esperion, a well-known entity in the biopharmaceutical industry trading under the Nasdaq symbol ESPR, has recently entered into a pivotal financial transaction with OMERS Life Sciences, a prominent investor in the life sciences sector. The essence of this transaction r...
What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of June 17-21.
Top 5 Buy Calls:
1. Skyworks upgraded to Buy at B. Riley
$Skyworks Solutions(SWKS.US)$
B. Riley upgraded Skyworks (SWKS) to Buy from Neutral with a price target of $130, up from $96, ahead of the July 8 through 11 SEM...
NEWS
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
The European Commission has approved label updates for NILEMDO (bempedoic acid) and NUSTENDI (bempedoic acid/ezetimibe) to treat hypercholesterolemia and reduce cardiovascular risk. This approval is based on the positi...
No comment yet